Med-psych drug-drug interactions update: Antihistamines

Psychosomatics

Volumn 44, Issue 5, 2003, Pages 430-434

  Armstrong, Scott C ^a,b   Cozza, Kelly L ^c,d  

^a Tuality Forest Grove Hospital   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALAVERT; ANTIARRHYTHMIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIRETROVIRUS AGENT; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CETIRIZINE; CIMETIDINE; CYCLOSPORIN; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DIPHENHYDRAMINE; EBASTINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; MACROLIDE; METOPROLOL; NEFAZODONE; NEUROLEPTIC AGENT; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; TERFENADINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; NON PRESCRIPTION DRUG;

BLOOD BRAIN BARRIER; CARDIOTOXICITY; CLINICAL TRIAL; DRUG METABOLISM; DRUG SAFETY; ENZYME INHIBITION; HEART ARRHYTHMIA; HUMAN; LIVER METABOLISM; REVIEW; SEDATION; SIDE EFFECT; DRUG ANTAGONISM; DRUG INTERACTION;

ASTEMIZOLE; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUGS, NON-PRESCRIPTION; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; TERFENADINE;

EID: 0142166228     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.44.5.430     Document Type: Article

References (31)

1. Armstrong SC, Cozza KL: Med-psych drug-drug interactions update. Psychosomatics 2002; 43:169-17
2. Woosley RL: Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 1996; 36:233-252
3. Finkle W, Adams J, Greenland S, Melmon KL: Increased risk of serious injury following an initial prescription for diphenhydramine. Ann Allergy Asthma Immunol 2002; 89:244-248
4. Chen C, Hanson E, Watson JW, Lee JS: P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 2003; 31:312-318
5. Sharma A, Hamelin BA: Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird's eye view. Curr Drug Metab 2003; 4:105-129
6. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J: In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos 1998; 26:536-539
7. Lessard E, Yessine M, Hamelin BA, Gauvin C, Labbe L, O'Hara G, LeBlanc J, Turgeon J: Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21:175-184
8. Hamelin BA, Bouayad A, Methot J, Jobin J, Desgagnes P, Poirier P, Allaire J, Dumesnil J, Turgeon J: Significant interaction between the nonprescription: antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP 2D6 activity. Clin Pharmacol Ther 2000; 67:466-477
9. Hait WN, Gesmonde JF, Murren JR, Yang JM, Chen HX, Reiss M: Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 1993; 45:401-406
10. Davies AJ, Harindra V, McEwan A, Ghose RR: Cardiotoxic effect with convulsions in terfenadine overdose. BMJ 1989; 298:325
11. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR Jr: Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264:2788-2790
12. Yap TG, Camm AJ: The current cardiac safety situation with antihistamines. Clin Exp Allergy 1999; 29(suppl 1):15-24
13. Renwick AG: The metabolism of antihistamines and drug interactions: the role of cytochrome P450 enzymes. Clin Exp Allergy 1999; 29(suppl 3):116-124
14. Slater JW, Zechnich AD, Haxby DG: Second generation antihistamines: a comparative review. Drugs 1999; 57:31-47
15. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD: The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001; 69:114-121
16. Craig-McFeely PM, Acharya NV, Shakir SA: Evaluation of the safety of fexofenadine from experience gained in general practice use in England in 1997. Eur J Clin Pharmacol 2001; 57:313-320
17. Armstrong SC, Cozza KL: Consultation-liaison psychiatry drug-drug interactions update. Psychosomatics 2001; 42:269-272
18. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD: Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71:414-420
19. Baltes E, Coupez R, Giezek H, Voss G, Meyerhoff C, Strolin Benedetti M: Absorption and disposition of levocetirizine, the eutomer of cetirizine, administered alone or as cetirizine to healthy volunteers. Fundam Clin Pharmacol 2001; 15:269-277
20. Claritin package insert. Kenilworth, NJ, Schering Corporation, Sept 2000
21. Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, Salazar DE: Loratadine and terfenadine interaction with nefazodone: both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 2001; 69:96-103
22. Geodon package insert. New York, Pfizer Roerig, July 2002
23. Barbey J: Loratadine/nefazodone interaction. Clin Pharmacol Ther 2002; 71:403
24. Kosoglou T, Salfi M, Lim JM, Batra VK, Cayen MN, Affrime MB: Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratidine with concomitant administration of ketoconazole or cimetidine. Br J Clin Pharmacol 2000; 50:581-589
25. Wang E, Casciano CN, Clement RP, Johnson WW: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab Dispos 2001; 29:1080-1083
26. McClellan K, Jarvis B: Desloratadine. Drugs 2001; 61:789-796
27. Desloratadine (Clarinex). Med Lett Drugs Ther 2002; 44:27-28
28. Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M: Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002; 41(suppl 1):29-35
29. Banfield C, Herron J, Keung A, Padhi D, Affrime M: Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002; 41(suppl 1):37-44
30. Henz BM: The pharmacologic profile of desloratadine: a review. Allergy 2001; 56:7-13
31. Geha RS, Meltzer EO: Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001; 107:751-762